Iris Formulation Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-07-2024
- Paid Up Capital ₹ 0.10 M
as on 07-07-2024
- Company Age 18 Year, 9 Months
- Last Filing with ROC 31 Mar 2017
- Revenue %
(FY 2017)
- Profit -129.89%
(FY 2017)
- Ebitda -129.89%
(FY 2017)
- Net Worth -3.34%
(FY 2017)
- Total Assets -99.80%
(FY 2017)
About Iris Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Praveen Mittal and Rakesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24230GJ2006PTC047660
- Company No.
047660
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2006
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location205, Elegance Productivity, Gujarat
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Iris Formulation?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Mittal  | Director | 03-Feb-2006 | Current |
| Rakesh Kumar | Director | 03-Feb-2006 | Current |
Financial Performance and Corporate Structure Insights of Iris Formulation.
Iris Formulation Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 129.89% decrease in profit. The company's net worth dipped by a decrease of 3.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iris Formulation?
In 2017, Iris Formulation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iris Formulation?
Unlock and access historical data on people associated with Iris Formulation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iris Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iris Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
